CD46 and myeloid sarcoma: In support to this theory, a clinical study indicated that increase in HHV-6A/B viral load was correlated to enhanced CD46 expression in MS patients [55], and several alterations in CD46 functions were described; the CD46-induced IL-10 secretion by T cells was strongly decreased [55], whereas the CD46-dependant IL-23 production by DC and IL-17 expression by T cells were enhanced [56, 57].